Stock market today: Nasdaq closes above 23,000 for first time as tech rebounds
LAGUNA HILLS, Calif. - Adagio Medical Holdings, Inc. (NASDAQ:ADGM), a medical device company with a current market capitalization of $25.07 million, announced Wednesday that acute results from its FULCRUM-VT U.S. pivotal study will be presented at The 20th Annual International Symposium on Ventricular Arrhythmias in Philadelphia on October 10-11, 2025.
The study evaluates the safety and effectiveness of Ultralow Temperature Cryoablation (ULTC) for treating Sustained Monomorphic Ventricular Tachycardia in patients with both ischemic and nonischemic cardiomyopathy.
"We are delighted that the FULCRUM-VT acute data will be featured as part of a late-breaking session at VT Symposium," said Todd Usen, Chief Executive Officer of Adagio Medical, in a press release statement. InvestingPro data shows the company maintains a healthy current ratio of 2.5, though it reported an EBITDA of -$30.34 million in the last twelve months.
The company’s technology will be featured in three presentations during the symposium. On October 10, Dr. Travis Richardson from Vanderbilt University Medical Center will present the interim analysis of acute outcomes from the FULCRUM-VT trial. Two additional presentations are scheduled for October 11, focusing on initial clinical experience and animal model studies of the technology.
The FULCRUM-VT study is enrolling 206 patients with structural heart disease who require catheter ablation of drug-refractory ventricular tachycardia. Results will support Adagio’s application for FDA premarket approval for its vCLAS Cryoablation System.
The system is currently available for treating monomorphic ventricular tachycardia in Europe and select markets but remains limited to investigational use in the United States.
Adagio Medical develops catheter-based Ultra-Low Temperature Cryoablation technology designed to create large, durable lesions through cardiac tissue for treating cardiac arrhythmias.
In other recent news, Adagio Medical Holdings, Inc. announced that Deborah Kaster will take on the role of Chief Financial Officer, effective September 5, 2025. Kaster, who is currently the Chief Business Officer, will replace Dan George, who has been serving as interim CFO since April 2025. In her expanded role, Kaster will oversee business development, corporate strategy, and investor relations, while also managing the company’s financial operations, including accounting, treasury, and financial planning. This leadership change marks a significant development for Adagio Medical as it continues to refine its executive team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.